Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
1ANZAC Research Institute, University of Sydney, Sydney NSW, Australia and Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany
2Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany
3Labor Limbach, Heidelberg, Germany
4Labor Limbach, Heidelberg, Germany and Unfortunately, Prof. Heinrich Schmidt-Gayk deceased while this work was in progress.
5Rehaklinik Saarschleife, Mettlach-Orscholz, Germany
6Orthopedic Studio, Völklingen, Germany
7Orthopedic Studio, St. Wendel, Germany
8Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany
9Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany
Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 12, Pages 1785–1792, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: 10.1515/CCLM.2007.352, December 2007
- Published Online:
Background: Hyperhomocysteinemia is a new risk factor for osteoporosis. This study analyzed the effect of a homocysteine (HCY)-lowering treatment in osteoporotic individuals.
Methods: Osteoporotic subjects (n=47, 55–82 years) were treated with either a combination of 2.5 mg folate, 0.5 mg vitamin B12 and 25 mg vitamin B6 or placebo. Bone mineral density (BMD) at lumbar spine and hip was measured at baseline and after 1 year. Urinary desoxypyridinoline cross-links (DPD) and plasma levels of tartrate resistant acid phosphatase (TRAP), C-terminal cross-links of collagen I (CTx), pro-collagen type I N-terminal peptide (PINP) and osteocalcin (OC) were measured after 0, 4, 8 and 12 months.
Results: B-vitamin supplementation significantly reduced HCY (0 vs. 12 months: 13.6±4.8 vs. 8.9±2.4 μmol/L). Placebo treatment had no effect on HCY (0 vs. 12 months: 12.0±3.4 vs. 12.7±3.9μmol/L). BMD, TRAP, CTx, OC and PINP did not change throughout the study in both groups. Vitamin treatment decreased urinary DPD by –13% (p<0.01) after 8 and 12 months. In a sub-group analysis of hyperhomocysteinemic subjects (HCY>15 μmol/L, n=8), B-vitamin treatment tended to increase BMD at the lumbar spine, with a t-score from –2.7 to –1.7, and to decrease OC and PINP by approximately 50%.
Conclusions: B-vitamin supplementation had no consistent effects on bone turnover or BMD. However, the situation may be different in patients with hyperhomocysteinemia.
Clin Chem Lab Med 2007;45:1785–92.
Keywords: bone mineral density; C-terminal telopeptides of collagen I (CTx); folate; homocysteine; osteocalcin; pro-collagen type I N-terminal peptide (PINP); tartrate-resistant acid phosphatase (TRAP); urinary desoxypyridinoline cross-links (DPD); vitamin B6; vitamin B12
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.